Clinical trials: Refractory Anemia in Systemic Lupus Erythematosis
Systemic Lupus Erythematosus (SLE), Idiopathic Inflammatory Myopathy (IIM)
Safety Study of CC312 in Autoimmune Disease Patients
This study is an open-label, multiple-dose escalation, Investigator-Initiated Trial (IIT) clinical trial designed to evaluate the safety and tolerability of CC312 in adult patients with relapsed and refractory autoimmune…
- Conditions
- Systemic Lupus Erythematosus (SLE), Idiopathic Inflammatory Myopathy (IIM), Systemic Sclerosis (SSc), Rheumatoid Arthritis (RA)
- Trial name
- NCT06888960
- Testing
- CC312
- Where
- China
- Volunteers
- 18 people
- Sponsor
- CytoCares Inc
Relapsed/Refractory Systemic Lupus Erythematosus, Relapsed/Refractory Systemic Sclerosis
Autologous CD19/BCMA Dual-Target CAR-T for Relapsed/Refractory Autoimmune Diseases
Autoimmune diseases occur when the immune system mistakenly attacks the body's own tissues, leading to chronic inflammation and damage to organs such as the kidneys, lungs, muscles, nerves, or blood cells.
- Conditions
- Relapsed/Refractory Systemic Lupus Erythematosus, Relapsed/Refractory Systemic Sclerosis, Relapsed/Refractory Idiopathic Inflammatory Myopathies, Relapsed/Refractory sjögren's Syndrome
- Trial name
- NCT07361094
- Testing
- Autologous CD19-BCMA Dual-Target CAR T-Cell Therapy
- Where
- China
- Sponsor
- Beijing Boren Hospital
Refractory Anemia in Systemic Lupus Erythematosis
Anemia in Systemic Lupus Erythematosus Specially Refractory Type
Systemic lupus erythroematosis (SLE) is a systemic autoimmune disease with multisystemic involvement. The condition has several phenotypes, with varying clinical presentations from mild mucocutaneous manifestations to multiorgan…
- Trial name
- NCT06210295
- Testing
- Laboratory investigtions
- Volunteers
- 67 people
- Sponsor
- Assiut University
Systemic Lupus Erythematosus, Autoimmune Hemolytic Anemia
UCAR T-cell Therapy Targeting CD19/ BCMA in Patients With Relapse/ Refractory Autoimmune Diseases
This is an investigator-initiated trial to evaluate the safety and efficacy of universal allogeneic anti-CD19/BCMA CAR T-cells in With Relapse/Refractory Autoimmune Diseases.
- Conditions
- Systemic Lupus Erythematosus, Autoimmune Hemolytic Anemia, Myasthenia Gravis, Systemic Sclerosis
- Trial name
- NCT06978738
- Testing
- universal allogeneic anti-CD19/BCMA CAR T-cells
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Changzhou No.2 People's Hospital
Autoimmune Hemolytic Anemia, Systemic Lupus Erythematosus
Reappraisal of the Therapies of Refractory Autoimmune Hemolytic Anemia in Systemic Lupus Erythematosus
There is a deficiency in guidelines about the treatment of autoimmune hemolytic anemia in systemic lupus erythematosus (SLE), especially in refractory cases.
- Trial name
- NCT05057481
- Testing
- Mycophenolate Mofetil 500mg, Rituximab
- Where
- Egypt
- Volunteers
- 30 people
- Sponsor
- Assiut University
Systemic Lupus Erythematosus (SLE)
A Study of LCAR-AIO in Subjects With Relapsed/Refractory Systemic Lupus Erythematosus
This is a prospective, single-arm, open-label, dose-exploration and expansion clinical study of LCAR-AIO in adult subjects with relapsed/refractory systemic lupus erythematosus.
- Trial name
- NCT06653556
- Testing
- LCAR-AIO T cells
- Where
- China
- Volunteers
- 3 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology